Lexaria Bioscience Corp.
LEXXNasdaq
$0.64
↑ +13.7%Jul 17 close · end-of-day
Price
1Y↓ -26.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$15.8M
Enterprise Value
$12.1M
P/E
—
P/S
81.3
P/B
3.3
EV/EBITDA
—
PEG
—
FCF Yield
-47.3%
Dividend Yield
—
Revenue (TTM)
$194,000.00
Net Income (TTM)
-$7.7M
Free Cash Flow (TTM)
-$7.5M
Gross Margin
100.0%
Operating Margin
-3973.2%
Net Margin
-3985.6%
ROE
-163.2%
ROIC
-555.5%
Debt / Equity
—
Net Cash
$3.6M
Return 1Y
-26.9%
Company profile
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x.
- CEO
- Christopher A. Bunka
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 7
- Headquarters
- British Columbia
- Website
- www.lexariabioscience.com
Management & directors
- Christopher RichardChief Executive Officer
- Carle VanessaSecretary
- Docherty John MartinPresident & CSO
Roles derived from SEC Form 4 filings.
Earnings
LEXX Q3 2026 Earnings
Period ends 2026-05-31
MetricActualYoY
Revenue$0.00↓ -100.0%
Diluted EPS-$0.08↓ -61.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $314,793.00 | $722,738.00 | $255,397.00 | $226,208.00 | $464,278.00 | $705,923.00 |
| Gross profit | $215,415.00 | $547,392.00 | $183,556.00 | $194,708.00 | $459,456.00 | $703,203.00 |
| Operating income | — | -$5.7M | -$6.6M | -$6.5M | -$5.8M | -$11.9M |
| Net income | -$4.1M | -$4.0M | -$7.3M | -$6.7M | -$5.8M | -$11.9M |
| Diluted EPS | — | — | — | -$1.01 | -$0.47 | -$0.66 |
| Operating cash flow | -$2.6M | -$4.0M | -$4.9M | -$5.9M | -$5.0M | -$10.5M |
| Free cash flow | -$2.6M | — | -$4.9M | -$5.9M | -$5.0M | -$10.5M |
| Gross margin | 68.4% | 75.7% | 71.9% | 86.1% | 99.0% | 99.6% |
| Operating margin | — | -786.8% | -2591.7% | -2888.5% | -1239.2% | -1683.0% |
| Net margin | -1297.6% | -557.2% | -2846.3% | -2946.4% | -1248.2% | -1686.0% |
| Line item | Q4 '24 | Q1 '24 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $84,000.00 | $183,923.00 | $174,000.00 | $174,000.00 | $174,000.00 | $0.00 | $20,000.00 | $0.00 |
| Gross profit | $84,000.00 | $181,203.00 | $174,000.00 | $174,000.00 | $174,000.00 | $0.00 | $20,000.00 | $0.00 |
| Operating income | -$2.2M | -$2.7M | -$2.8M | -$3.8M | -$2.7M | -$1.6M | -$1.5M | -$2.0M |
| Net income | -$2.2M | -$2.7M | -$2.7M | -$3.8M | -$2.7M | -$1.6M | -$1.4M | -$2.0M |
| Diluted EPS | -$0.15 | -$0.16 | -$0.15 | -$0.21 | -$0.14 | -$0.07 | -$0.06 | -$0.08 |
| Operating cash flow | -$1.9M | -$2.7M | -$1.5M | -$3.6M | -$2.6M | -$984,098.00 | -$2.2M | -$1.6M |
| Free cash flow | -$1.9M | -$2.8M | -$1.5M | -$3.6M | -$2.6M | -$984,098.00 | -$2.2M | -$1.6M |
| Gross margin | 100.0% | 98.5% | 100.0% | 100.0% | 100.0% | — | 100.0% | — |
| Operating margin | -2622.7% | -1463.0% | -1581.0% | -2155.4% | -1545.2% | — | -7259.5% | — |
| Net margin | -2600.9% | -1470.0% | -1559.3% | -2177.6% | -1549.3% | — | -7249.9% | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-17 | BUNKA CHRISTOPHER | Gift | 100,000 | $0.00 | $0.00 | filing |
| 2025-07-30 | BUNKA CHRISTOPHER | Buy | 11,900 | $0.91 | $10,865.89 | filing |
| 2025-07-29 | BUNKA CHRISTOPHER | Buy | 15,600 | $0.92 | $14,375.40 | filing |
| 2025-07-29 | CHRISTOPHER RICHARD· Chief Executive Officer | Buy | 15,000 | $0.91 | $13,641.00 | filing |
| 2025-07-29 | DOCHERTY JOHN MARTIN· President & CSO | Buy | 5,376 | $0.93 | $4,988.93 | filing |
| 2025-07-29 | McKechnie William Edward | Buy | 5,000 | $0.91 | $4,531.50 | filing |
| 2025-07-29 | Carle Vanessa· Secretary | Buy | 750 | $0.91 | $682.50 | filing |
Latest 7 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.